Pharmacokinetics of mepindolol sulphate in animals

Pharmacokinetics of mepindolol in patients with chronic renal failure

Five patients with a creatinine clearance of 14 to 37 ml/min/1.73 m2 were each given an oral dose of 10 mg of the beta-blocker mepindolol sulphate (Corindolan). In addition, two dialysis patients received the same dose either during hemodialysis or on a dialysis-free day. Plasma levels of mepindolol were measured by a sensitive, specific HPLC method. Mepindolol was rapidly absorbed in all the patients. The maximum plasma level of 35 +/- 8 ng/ml was reached after 1.4 +/- 0.5 h. The half-life of disposition was 4.0 +/- 1.5 h. The area under the plasma concentration-time curve was 237 +/- 84 ng X h/ml. The data obtained were no different from those found in normal healthy volunteers.

Transfer of mepindolol to newborns by breast-feeding mothers after single and repeated daily doses

The concentrations of mepindolol in plasma and milk of five breastfeeding mothers were determined after 1 and 5 daily doses of mepindolol sulphate 20 mg. In the newborns plasma levels were measured once on the first and fifth days of the study. The mean maternal plasma concentration of mepindolol 2 h after administration was 52 ng/ml both after 1 and 5 doses; in the milk 18 and 22 ng/ml the corresponding concentrations were. The average plasma/milk drug concentration ratio was 2.6 +/- 1.6. Plasma levels in the newborn were below the detection limit of 1 ng/ml, except for one baby in whom 2 and 5 ng/ml, respectively, were found 4 h after one and five maternal doses.